Iperion relies on related-party funding as Pathoglaze plant relocates

Lower Loss, Sharply Reduced Balance Sheet

Iperion Limited (NZX:IPR) has reduced its annual loss, but the improvement came against a much thinner financial base. The company reported a net loss of $294,595 for the year ended 31 March 2026, down from $455,683 a year earlier, while cash and term deposits fell to $155,492 from $425,341. Net assets dropped to $53,803 from $348,398.

The figures reflect a business conserving cash rather than one yet showing commercial scale. Iperion said it earned only $10 of interest income after keeping funds available to cover costs associated with an anticipated sales order. Administrative expenses fell to $294,605 from $317,781, while the outsourced manufacturing plant fee was fully discounted for the year and the prior year’s trademark impairment expense did not recur.

Related-Party Facility Underpins Working Capital

The funding position is being supported by Elitesoft Asia, a company related to majority shareholder and director Chang Ku EE. Under a loan agreement, Elitesoft provides a $250,000 facility at 8% interest, described as the Hong Kong Monetary Authority Base Rate plus 4%. Any increase to US$1 million would require shareholder approval.

Mr EE has also confirmed that he will provide financial support if required to meet working capital obligations and liabilities as they fall due for at least 12 months from the 30 June 2026 approval date of the financial statements. Since January, Iperion has deferred payment of 50% of directors’ fees and 33% of the management fee until sales are sufficient to move the company to positive cash flow.

Pathoglaze Production Moves to Singapore

Iperion’s manufacturing infrastructure is in transition. The vendor is relocating the Pathoglaze plant from Malaysia to Singapore, with the equipment currently in storage. The company said enough compound has already been produced to fill sales orders while the new facility is established, with smaller product batches and ongoing development supported from the licensor’s Singapore facilities.

The company also said customer and revenue performance targets under its exclusive worldwide Pathoglaze licence have been permanently waived. During the year, development focused on antimicrobial polymer jute bags for cocoa and coffee transport in collaboration with a multinational chocolate manufacturer, while product tests and trials continued with potential customers. No confirmed sales order value or timing was disclosed in the presentation.

Product Claims Remain Ahead of Commercial Proof

Pathoglaze was presented as a zinc-based antimicrobial additive that can be incorporated into plastics, polymers and coatings. Iperion highlighted company-reported test results of up to 99.9% antimicrobial activity under ISO 22196, including at a 0.5% loading in some polymer applications, as well as potential uses in packaging, housewares, construction materials, healthcare products and fitness equipment.

Those claims describe the product’s proposed capabilities and application range, not disclosed revenue or secured customer contracts. The immediate investment question is therefore less about the breadth of the presentation than whether trials convert into orders before the company’s reduced cash reserves and fee deferrals become a more pressing constraint.